Skip to content

Causal test of right anterolateral prefrontal cortex (ralPFC) involvement in fear and response inhibition.

Causal test of right anterolateral prefrontal cortex (ralPFC) involvement in fear and response inhibition. - Right anterolateral prefrontal cortex, fear and response inhibition.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45731
Enrollment
56
Registered
2017-04-03
Start date
2017-10-18
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety disorder fear regulation

Interventions

Participants visit the laboratory on two separate days, and receive 40 sec. slow-repetitive TMS stimulation at 70% of the motor threshold to the right side of their forehead on one of the days, and

Sponsors

Universiteit Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age between 18 and 45. - Right-handedness. - Written informed consent.

Exclusion criteria

Exclusion criteria: Violation of standard TMS safety criteria (Rossi, Hallett, Rossini, & Pascual-Leone, 2009; see also Appendix F1.1: TMS screenings questionnaire): - Incapability of giving an informed consent - Ferrous objects in or around the head (e.g. braces, pacemaker, metal fragments) - History of closed- or open-head injury - History of epilepsy - History of epilepsy in first-degree relatives - History of neurological or psychiatric illness - Major medical history - Drug or alcohol abuse over a period of six months prior to the experiment - Pregnancy

Design outcomes

Primary

MeasureTime frame
The main study parameter for study 1 is the effect of TMS stimulation on the reduction in FPS at offset of a threat cue, for study 2 the increase in SSRT (behaviourally) and concomitant decrease of N1 (derived from the EEG).

Secondary

MeasureTime frame
N/A.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)